Doximity price target lowered to $49 from $65 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Doximity (DOCS) to $49 from $65 and keeps an Overweight rating on the shares. A disappointing outlook “amplifies concerns,” but the after-hours stock move to the firm’s new bear case will likely prove to be an “overreaction,” the analyst tells investors in a post-earnings note.